Background/Objective: Patients with moderate plaque psoriasis (ie, 5–10% psoriasis-
involved Body Surface Area [BSA]) often receive no treatment or are undertreated with …

Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in clinical trials in
patients with moderate plaque psoriasis (affected body surface area [BSA] 5% to 10%) …

Introduction: Psoriasis is a chronic inflammatory skin disease characterized by erythematous
plaques on extensor surfaces, scalp, and back. Current therapies for psoriasis are limited by …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

Background Difficult-to-treat palmoplantar psoriasis has a disproportionately negative
impact on quality of life. Objective We evaluated the efficacy and safety of apremilast in …

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …

Psoriasis is a chronic, inflammatory, immune‐mediated disease of the skin and joints.
Plaque psoriasis is the most common clinical phenotype of psoriasis. Apremilast is an oral …

INTRODUCTION: Many options are available for patients with moderate to severe plaque
psoriasis. Patients with moderate disease, however, are often undertreated and do not …

Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …

Apremilast is a phosphodiesterase-4 inhibitor taken orally. Little information about its use in
routine clinical practice is available. We aimed to assess treatment safety and persistence …